Lenalidomide and Rituximab for Untreated Indolent Lymphoma: Final Results of a Phase II Study


Lenalidomide and Rituximab for Untreated Indolent Lymphoma: Final Results of a Phase II Study
Slides from a presentation at ASH 2012 and transcribed comments from a recent interview with Bruce D Cheson, MD (1/14/13)
Fowler NH et al. Lenalidomide and rituximab for untreated indolent lymphoma: Final results of a Phase II study. Proc ASH 2012;Abstract 901.

Dr Cheson is Professor of Medicine, Deputy Chief of the Division of Hematology-Oncology and Head of Hematology at the Georgetown University Hospital Lombardi Comprehensive Cancer Center in Washington, DC.